Peter Delange - ReShape Lifesciences President
| RSLS Stock | USD 0.17 0.01 6.25% |
President
Mr. Peter Delange serves as Senior Vice President Operations and Business Development of the Company. Mr. DeLange has served as our Senior Vice President of Operations and Business Development since January 18, 2016 since 2016.
| Age | 47 |
| Tenure | 8 years |
| Address | 1001 Calle Amanecer, San Clemente, CA, United States, 92673 |
| Phone | 949 429 6680 |
| Web | https://www.reshapelifesciences.com |
ReShape Lifesciences Management Efficiency
The company has return on total asset (ROA) of (0.8392) % which means that it has lost $0.8392 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2059) %, meaning that it created substantial loss on money invested by shareholders. ReShape Lifesciences' management efficiency ratios could be used to measure how well ReShape Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.11 in 2024. Return On Capital Employed is likely to drop to -2.21 in 2024. At this time, ReShape Lifesciences' Total Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 4 M in 2024, whereas Other Assets are likely to drop slightly above 111.4 K in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Christopher David | Novo Integrated Sciences | 65 | |
| Troy Villarreal | HCA Holdings | N/A | |
| Charles Hall | HCA Holdings | 71 | |
| Juan Vallarino | HCA Holdings | 54 | |
| Jane Englebright | HCA Holdings | 62 | |
| Joseph Sowell | HCA Holdings | 64 | |
| Jeff Cohen | HCA Holdings | 49 | |
| Randall Goldberg | Acadia Healthcare | 41 | |
| Sandra Morgan | HCA Holdings | 57 | |
| William Morrow | HCA Holdings | 48 | |
| Bruce Moore | HCA Holdings | 52 | |
| Heather Rohan | HCA Holdings | N/A | |
| Phillip Billington | HCA Holdings | 56 | |
| Paul Paslick | HCA Holdings | 61 | |
| Kathryn Torres | HCA Holdings | 57 | |
| Donald Stinnett | HCA Holdings | 58 | |
| Timothy McManus | HCA Holdings | 52 | |
| Tim McManus | HCA Holdings | N/A | |
| Jonathan Perlin | HCA Holdings | 58 | |
| Ravi Chari | HCA Holdings | 51 | |
| Michael Cuffe | HCA Holdings | 55 | |
Management Performance
| Return On Equity | -2.21 | ||||
| Return On Asset | -0.84 |
ReShape Lifesciences Leadership Team
Elected by the shareholders, the ReShape Lifesciences' board of directors comprises two types of representatives: ReShape Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ReShape. The board's role is to monitor ReShape Lifesciences' management team and ensure that shareholders' interests are well served. ReShape Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ReShape Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Delange, Senior Vice President - Operations and Business Development | ||
| Jon Tremmel, Independent Director | ||
| Barton Bandy, President CEO, Director | ||
| DVM DVM, VP Officer | ||
| MBA DVM, VP Officer | ||
| Scott Youngstrom, CFO, Chief Compliance Officer | ||
| Dan Gladney, Chairman of the Board and Presidentident, CEO | ||
| Kevin Condrin, Senior Vice President - Commercial | ||
| Al Diaz, Vice RD | ||
| Thomas Stankovich, Chief Officer | ||
| Michael Mashaal, Director | ||
| Gary Blackford, Director | ||
| Lori McDougal, Director | ||
| Arda Minocherhomjee, Independent Director | ||
| Jody Dahlman, Director Communications | ||
| Katherine Tweden, CoFounder | ||
| Paul Hickey, Senior Vice President - Marketing and Reimbursement | ||
| Mark Knudson, CoFounder CEO | ||
| Naqeeb Ansari, Senior Vice President - Sales | ||
| Bobby Griffin, Independent Director |
ReShape Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ReShape Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.21 | ||||
| Return On Asset | -0.84 | ||||
| Profit Margin | (1.31) % | ||||
| Operating Margin | (0.96) % | ||||
| Current Valuation | (303.12 K) | ||||
| Shares Outstanding | 23.46 M | ||||
| Shares Owned By Insiders | 11.16 % | ||||
| Shares Owned By Institutions | 1.96 % | ||||
| Number Of Shares Shorted | 487.78 K | ||||
| Price To Book | 0.58 X |
Currently Active Assets on Macroaxis
When determining whether ReShape Lifesciences is a strong investment it is important to analyze ReShape Lifesciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ReShape Lifesciences' future performance. For an informed investment choice regarding ReShape Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ReShape Lifesciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for ReShape Stock analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is ReShape Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ReShape Lifesciences. If investors know ReShape will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ReShape Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 1.457 | Quarterly Revenue Growth (0.36) | Return On Assets (0.84) | Return On Equity (2.21) |
The market value of ReShape Lifesciences is measured differently than its book value, which is the value of ReShape that is recorded on the company's balance sheet. Investors also form their own opinion of ReShape Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is ReShape Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ReShape Lifesciences' market value can be influenced by many factors that don't directly affect ReShape Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ReShape Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ReShape Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ReShape Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.